

**JOINT STATEMENT ON THE REGULATORY FREEZE DELAYING IMPLEMENTATION
OF THE EXECUTIVE ORDER ON ACCESS TO LIFE-SAVING MEDICATIONS**

January 26, 2021

The Biden Administration's decision to delay implementation of pending federal rules is to be expected. Incoming administrations commonly enact Regulatory Freeze Pending Review to allow department and agency appointees or designees adequate time to review regulations that have not yet taken effect.

The announcement sparked a strong response within the diabetes community because it delays implementation of the Executive Order on Access to Life-Saving Medications from January 22 to March 22, 2021. This order requires certain health centers to extend 340B net prices on insulin and injectable epinephrine to their low-income uninsured or underinsured patients.

The Diabetes Leadership Council (DLC) and Diabetes Patient Advocacy Coalition (DPAC) support state and federal policies that secure zero or low consumer cost sharing for lifesaving insulin, and first dollar, preventive coverage for all diabetes medicines, medical devices, supplies, services and technologies.

Once the Biden Administration has reviewed the executive order and final rule, we hope they will agree unemployed, uninsured and underinsured Americans who rely on the nation's safety net providers should benefit from deeply discounted 340B prices.

Insulin is available through 340B for pennies per unit. We recognize most 340B entities extend those savings to most of their patients, but insulin is an essential medicine and should be available at or below net cost to all eligible patients, particularly in the midst of a global pandemic and public health emergency.

DLC and DPAC will continue working with policymakers on both sides of the aisle to advance policies that strengthen the nation's public health care system, and secure effective, affordable, individualized care for every person with diabetes.